Format

Send to

Choose Destination
Cardiol Rev. 2017 Nov/Dec;25(6):315-320. doi: 10.1097/CRD.0000000000000169.

Neprilysin Inhibition and the Treatment of Heart Failure: Recent Steps in the Right Direction.

Author information

1
From the *Departments of Medicine, University of Rochester/Strong Memorial Hospital, Rochester, NY; and †New York Medical College/Westchester Medical Center, Valhalla, NY.

Abstract

Numerous investigators have attempted to target the natriuretic peptide system in the treatment of heart failure since it was first described over 30 years ago. The history of neprilysin inhibition as a treatment for heart failure has been characterized by numerous setbacks. Recently, the PARADIGM-HF trial has shown favorable results, which may bring neprilysin inhibition into the mainstream of clinical practice. This article will review the history of the natriuretic peptide system and the investigations into it as a target for heart failure treatment, culminating in the positive results of the PARADIGM-HF trial, as well as planned and potential future directions for research.

PMID:
28984670
DOI:
10.1097/CRD.0000000000000169
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center